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Abstract
Background: Given that helminth infections are thought to have strong immunomodulatory activity, the question
whether helminth infections might affect responses to malaria antigens needs to be addressed. Different cross-
sectional studies using diverse methodologies have reported that helminth infections might either exacerbate or
reduce the severity of malaria attacks. The same discrepancies have been reported for parasitemia.
Methods/Design: To determine the effect of geohelminth infections and their treatment on malaria infection and
disease outcome, as well as on immunological parameters, the area of Nangapanda on Flores Island, Indonesia,
where malaria and helminth parasites are co-endemic was selected for a longitudinal study. Here a Double-blind
randomized trial will be performed, incorporating repeated treatment with albendazole (400 mg) or placebo at three
monthly intervals. Household characteristic data, anthropometry, the presence of intestinal helminth and Plasmodium
spp infections, and the incidence of malaria episodes are recorded. In vitro cultures of whole blood, stimulated with a
number of antigens, mitogens and toll like receptor ligands provide relevant immunological parameters at baseline
and following 1 and 2 years of treatment rounds. The primary outcome of the study is the prevalence of Plasmodium
falciparum and P. vivax infection. The secondary outcome will be incidence and severity of malaria episodes detected
via both passive and active follow-up. The tertiary outcome is the inflammatory cytokine profile in response to
parasite antigens. The project also facilitates the transfer of state of the art methodologies and technologies,
molecular diagnosis of parasitic diseases, immunology and epidemiology from Europe to Indonesia.
Discussion: The study will provide data on the effect of helminth infections on malaria. It will also give
information on anthelminthic treatment efficacy and effectiveness and could help develop evidence-based
policymaking.
Trial registration: This study was approved by The Ethical Committee of Faculty of Medicine, University of
Indonesia, ref:194/PT02.FK/Etik/2006 and has been filed by ethics committee of the Leiden University Medical
Center. Clinical trial number:ISRCTN83830814. The study is reported in accordance with the CONSORT guidelines for
cluster-randomized studies.
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Worldwide, more than a billion people are infected by
geohelminths, with a majority harboring roundworms
(Ascaris lumbricoides), whipworms (Trichuris trichiura),
and/or hookworms (Necator americanus or Ancylostoma
duodenale) [1-3]. Such helminths modify the immune
system to induce predominant production of T-helper-2
(Th2) cytokines (interleukin/IL-4, IL-5, IL-9, IL-10, IL-
13), associated with increased levels of immunoglobulin
E (IgE) and eosinophilia [4,5]. Another hallmark of
chronic helminth infections is their ability to induce a
strong regulatory network characterized by T cell hypor-
esponsiveness and the increased production of suppres-
s i v ec y t o k i n e ss u c ha sI L - 1 0a n dT G F - b [6]. Their
ability to induce regulatory responses is thought to be
advantageous for both the parasite and the host as it
allows the survival of the parasite for extended periods
of time within the host while preventing overt patholo-
gical reactions that would otherwise be damaging to the
host [7]. The latter may explain why such helminth
infections rarely result in overt clinical manifestations.
Although the immunological consequences of hel-
minth infections primarily reflect responses directed
towards helminth antigens, there may be spill-over
effects on responses to unrelated antigens [6,8].
Whereas the marked Th2 polarization may compete
with Th1 cytokines to affect the magnitude of a Th1
response to an incoming antigen, a strong regulatory
response can dampen immune reactivity of both Th1
and Th2 types to a third party antigen. Not surprisingly,
then, it is argued that helminth infections might modu-
late the human immune response to common co-infec-
tions such as malaria, TB and HIV/AIDS [9-11].
Malaria itself is one of the most serious infectious dis-
eases, infecting 5-10% of the world’sp o p u l a t i o n ,w i t h
300-600 million cases and more than 2 million deaths
annually [12]. In areas of high malaria transmission, the
burden of disease is borne by infants and young children
[13,14], whilst, in areas of lower transmission, primary
infection might also occur later in life, causing severe
illness [12,15,16].
Co-infection is the norm in nature [9,17], since hel-
minth infections of different species are often endemic
in the same communities that are exposed to infection
with plasmodia [18]. The question of whether helminth
infections affect the course of malaria has been
addressed in various reports [19] in the past few years.
Only a small number of papers report on population
studies and most of them were cross-sectional in nature,
which in contrast to longitudinal studies might not be
able to demonstrate the actual dynamics of infection.
An early study by Murray and colleagues (1977) in a
malnourished population at Anjouan, Comoros Islands
suggest that A. lumbricoides might suppress malaria
symptoms [20]. Since then studies of co-infections have
shown helminths to either exacerbate [21] or reduce
[22-24] the severity of malaria. The reasons for conflict-
ing data on the effect of helminth co-infection on
malaria disease outcomes could be due to differences in
study design, study groups, and possibly, most impor-
tantly, the helminth species investigated [18,25].
Although helminth infections are considered as patho-
gens, it is clear that their course of infection is relatively
free of overt clinical manifestations and in recent years
several reports have shown their suppressive effect on
diseases such as allergy [3,26], autoimmunity [27], and
inflammatory bowel disease [28], highlighting a possible
beneficial effect on inflammation [29]. To assess the
influence of helminth infections on inflammatory dis-
eases taking into account environmental and genetic
influences in a longitudinal setting, the ImmunoSPIN
project http://www.immunospin.org has been initiated.
As part of the project ImmunoSPIN, the helminth-
malaria sub project (ImmunoSPIN-Malaria) was
designed to determine whether and how helminth infec-
tions may affect the course of a malaria infection. This
study is a double-blind randomized trial of placebo and
anthelminthic treatment to elucidate the impact of hel-
minth infections on malaria longitudinally in an area
where helminth infections and malaria coexist. It is
expected to provide new information and contribute to
our understanding of how regulatory responses that may
be induced by chronic helminth infections affect inflam-
matory conditions, especially on malaria infection.
This paper presents the rationale of the ImmunoSPIN-
Malaria study that, at the clinical and biological level,
aims to discern plausible and meaningful interactions
between these infections.
Methods/Design
Study area and population
Nangapanda is a sub-district of the Ende district, Flores
Island, Indonesia and is situated in a coastal area with a
population of about 22000 (Figure 1). Situated near the
equator (8°45’S, 121°40’E)[30], it is characterized by a
uniform high temperature, in the range of 23-33.5°C,
with humidity of 86-95%. Average yearly rain fall is
1.822 mm with about 82 rainy days, especially from
November to April, with the peak in December until
March. Malaria is reported to be highly prevalent in this
area [31]. Preliminary surveys conducted in 2005 and
2006 found this area to be endemic for geohelminths
(A. lumbricoides, hookworms and T. trichiura)a n d
malaria parasites (P. falciparum and P. vivax). The sub-
district is divided into villages of which those located
near the primary health centre (Puskesmas), Ndeturea,
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PIN-Malaria study.
T h em a j o r i t yi nt h es t u d ya r e ai sE n d et r i b ea n d
migrants from neighbouring district of Bajawa that have
populated the island for more than 300 years. Most indivi-
duals work as farmers and grow their own food. Recently
also government employees and individuals owning small
businesses moved to the area. Individuals with Chinese
and Arabic ethnicity have come to the area about 200
years ago and most of them, run business corporations
with other tribes. There are very few other tribes from
outside of Flores and most of them were brought from
outside by marriage with Flores natives. The Nangapanda
population is dynamic and individuals shift address within
t h ea r e aa sw e l la sm o v ei na n do u to ft h ea r e af o rp u r -
poses of studying, marriage, or searching for jobs.
Study design, data and sample collection
Baseline mapping of houses by Global Positioning Sys-
tem (GPS) system has allowed maps to be generated
using ArcGIS 9,1 software (ESRI, USA). In order to per-
form spatial analyses based on individual data, geogra-
phical coordinates were assigned to each individual as
well as centroid coordinates to households.
Community workers were recruited and trained to do
questionnaires, follow-ups, malaria surveys (finger
prick), and distribute treatment or placebo, as well as
doing health promotion among the population. Each
community worker will be in charge of a certain num-
ber of households that they visit monthly for recording
movement and active follow-up of malaria symptoms,
and three monthly for finger pricking and distributing
the treatment.
Figure 1 The map of the study area in Nangapanda, Flores, Indonesia.
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trial with two arms. One arm is treatment with albenda-
zole (single dose of 400 mg) [32], while the other arm is
treatment with matching placebo (both tablets from PT
Indofarma Pharmaceutical, Bandung, Indonesia). The
treatment is provided every three months for a period
of two years (a total of 8 treatments) to everyone, except
children below two years of age, pregnant women or
severely ill persons. Computer aided block randomiza-
tion by household, using Random Allocation Software
[33] will be assigned to the treated and placebo groups.
The treatment is coded as A or B and the codes are
concealed from investigators and patients. Labels with
the study subject ID are printed from a computer data-
base and attached to the appropriate strip of treatment
b yas e p a r a t et e a ml o c a t e di nJ a k a r t aw i t h o u tt h ei n v o l -
vement of the study investigators. An interim analysis
will be performed by the monitoring committee, 1 year
after treatment to test for any adverse effects that reten-
tion of anthelminthic treatment might have on the
growth of children and on the incidence of malaria epi-
sodes (in contrast to the hypothesis being tested). If the
trial continues, the final unblinding of the codes will
take place two years after treatment.
On approval of individuals in the area, peripheral
blood will be collected from a subset of individuals over
4 years of age that were randomly selected for whole
blood culture based on households. The assay will be
done at baseline, 1 and 2 years after treatment. For
those who are not included in whole blood assays,
malaria evaluation by finger pricking will be obtained
aiming to include the whole population in the study
area.
Every household receives a card identifying all family
members. This card is used when community workers
visit homes and when family members visit the Puskes-
mas. Data on socioeconomic status and health status is
collected at baseline and 2 years after treatment using
questionnaires in Bahasa Indonesia. Monthly data such
as birth, death and migration will be recorded. New-
borns and individuals who enter the study area will be
registered with a newly assigned ID number as well as
their geographical coordinates. Active follow-up includes
a questionnaire with questions on clinical complaints in
general and clinical malaria in particular and will be
conducted monthly by community workers. In addition
to the questionnaire, blood slides will be collected at
three monthly intervals to test for plasmodia. For exami-
nation of intestinal helminths, stool samples will be col-
lected yearly. Samples will be used for microscopy and
PCR analyses. Passive follow-up will be held in colla-
boration with the Puskesmas that keeps clinical records
of individuals that visit either for consultation or for
overnight admission, including information on diagnosis
and treatment. If malaria is suspected, two blood slides
will be collected: one to be examined by the Puskesmas
staff and another for re-examination by the research
team in Jakarta at the Department of Parasitology, Uni-
versity of Indonesia (UI).
All blood samples (serum, cell pellet, plasma, and
whole blood), blood culture supernatants, as well as
stool samples for PCR, will be kept at -20°C in a tem-
perature recorded freezer which is checked twice a day
and will be sent to Jakarta on dry ice for storage -20°C
or -80°C.
Outcomes and case definitions
The study aims to determine whether and how helminth
i n f e c t i o n sm a ya f f e c tt h ec o u r s eo fi n f e c t i o nw i t h
malaria parasites and disease outcome. Therefore we
will monitor disease in individuals treated with albenda-
zole compared to placebo. The primary outcome is the
prevalence of infection with P. falciparum and P. vivax
up to 2 years after treatment, the secondary outcome is
the incidence and severity of malaria recorded as a
result of passive and active follow-up up to 2 years after
treatment. The tertiary outcome is the inflammatory
cytokine responses to P. falciparum antigens 1 and
2 years after treatment.
Helminth and plasmodia infections will be defined by
the presence of parasites detected by microscopic exam-
ination of stool and blood samples respectively and will
be confirmed by molecular (PCR-based) methods
[34-38]. A malaria case is defined as an individual with
typical malaria symptoms and a blood slide containing
plasmodia asexual forms. Typical malaria case defini-
tions: fever (oral temperature ≥ 37.5°C) and/or history
of fever in the past 48 hours with a positive slide (P.
vivax ≥ 250/ul, P. falciparum ≥ 1000/ul). Asymptomatic
carriers have a blood slide positive for P. falciparum
and/or P. vivax asexual forms, as well as positive result
by PCR and no concomitant clinical symptoms. Sus-
pected malaria cases are defined as individuals who
report symptoms typical of malaria but for whom no
slide is available at the time of presentation with
symptoms.
Parasitological examination
Stool examination by microscopy
The Harada Mori method will be carried out on fresh
stool samples to detect hookworm larvae. A certain
amount of each stool sample is preserved in formalin
( 4 % )a n dk e p ta tr o o mt e m p e r a t u r ef o rm i c r o s c o p i c
examination. The formol-ether acetate concentration
method [39] is performed on the formalin preserved
stool samples followed by microscopical examination for
intestinal helminth infections, as well as protozoan
infections. For hookworm detection, an amount of fresh
Wiria et al. BMC Infectious Diseases 2010, 10:77
http://www.biomedcentral.com/1471-2334/10/77
Page 4 of 12stool sample is incubated using filter paper soaked by
distilled water inside sealed plastic tubes according to
the Harada Mori method [40].
Stool examination by real-time PCR
For DNA isolation from stool, approximately 100 mg
unpreserved faeces (that was kept at -20°C) are sus-
pended in 200 μl PBS containing 2% polyvinylpolypyroli-
done (PVPP; Sigma, Steinheim, Germany). DNA
isolation and setup of the PCR reactions are performed
using a custom-made Hamilton robot platform (made in
Germany). After heating for 10 min at 100°C suspen-
sions are treated with sodium dodecylsulphate-protei-
nase K for 2 h at 55°C. DNA is isolated using QIAamp
DNA-easy 96-well plates (QIAgen, Venlo, The Nether-
lands) [36]. Within the isolation lysis buffer, 10
3 PFU/ml
Phocine herpes virus 1 (PhHV-1) is added to serve as an
internal control [41].
A. duodenale, N. americanus (hookworm), A. lumbricoides,
S. stercoralis real-time PCR (ANAS-PCR) [or just “helminth
rt-PCR"]
Sequences of the A. duodenale-, N. americanus-,a n dS.
stercoralis-specific primers and probes are used as
described previously [37,38] with some modifications in
fluorophore- and quencher-chemistry. Minor groove
binding (MGB) probes are replaced by XS probes (Biole-
gio, Malden, The Netherlands) and to accommodate the
specific fluorophor combination of the CFX real-time
PCR system (Bio-Rad laboratories, USA) the A. duode-
nale specific XS-probe is labelled with Texas Red and the
S. stercoralis-specific probe is labelled with Quasar-705.
The A. lumbricoides-specific primers and probe are cho-
sen using Primer Express software (Applied Biosystems,
Foster City, CA), from the internal transcribed-spacer-1
(ITS1) sequence of A. lumbricoides (GenBank accession
ALJ000895). The A. lumbricoides-specific primers,
Alum96F 5’-GTAATAGCAGTCGGCGGTTTCTT-3’
and Alum183R 5’-GCCCAACATGCCACCTATTC-3’
amplify an 87-bp fragment of the ITS1 sequence and the
XS-probe Alum124T Yakima Yellow-5’-TTGGCGGA-
CAATTGCATGCGAT-3’-XS is used to detect the A.
lumbricoides-specific product. The real-time PCRs were
optimized first as monoplex assays with 10-fold dilution
series of A. duodenale, N. americanus, A. lumbricoides,
and S. stercoralis DNA, respectively. The monoplex real-
time PCRs were thereafter compared with the multiplex
PCR with the PhHV internal control. The cycle threshold
(Ct) values obtained from testing the dilution series of
each pathogen in both the individual assay and the multi-
plex assay were similar, and the same analytical sensitivity
was achieved. The multiplex ANAS PCR showed 100%
specificity when tested against 145 DNA controls derived
from a wide range of intestinal microorganisms [35].
Amplification reactions are performed in white PCR
plates in a volume of 25 μl with PCR buffer (HotstarTaq
master mix, QIAgen, Germany), 5 mM MgCl2, 2.5
μgram Bovine Serum Albumin (Roche Diagnostics
Nederland B.V., Almere, the Netherlands), 5 pmol of
each A. duodenale-specific primer, and of each N. amer-
icanus-specific primer, 2 pmol of each A. lumbricoides-
specific primer, 2.5 pmol of each S. stercoralis-specific
primer and 3.75 pmol of each PhHV-1-specific primer,
1.25 pmol of each N. americanus-specific XS-probe, A.
lumbricoides-specific XS-probe, S. stercoralis-specific
double-labelled probe, and PhHV-1-specific double-
labelled probe, and 2.5 pmol of the A. duodenale-speci-
fic XS-probe, and 5 μl of the DNA sample.
Amplification consists of 15 min at 95°C followed by 50
cycles of 15 s at 95°C, 30 s at 60°C, and 30 s at 72°C.
Amplification, detection, and analysis are performed with
the CFX real-time detection system (Bio-Rad laboratories).
The PCR output from this system consists of a cycle-
threshold (Ct) value, representing the amplification cycle
in which the level of fluorescent signal exceeds the back-
ground fluorescence, and reflecting the parasite-specific
DNA load in the sample tested. Negative and positive con-
trol samples are included in each amplification run.
The amplification is considered to be hampered by
faecal inhibitory factors if the expected cycle threshold
(Ct) value of 33 in the PhHV-specific PCR is increased
by more than 3.3 cycles.
Blood examination by microscopy
To detect P .f a l c i p a r u m ,P .v i v a x ,P .m a l a r i a e ,a n dP.
ovale, blood slides (thick and thin) are stained with
Giemsa [42] followed by microscopic examination [43].
Blood examination by real-time PCR
DNA was isolated from 200 μl blood with QIAamp
DNA-easy 96-well plates according to the manufac-
turer’s recommendations. DNA isolation and setup of
the PCR reactions are performed using a custom-made
Hamilton robot platform.
P. falciparum, P. vivax, P. ovale, and P. malariae (malaria)
real-time PCR
Sequences of the Plasmodium-specific primers and the
P .f a l c i p a r u m ,P .v i v a x ,P .o v a l e ,a n dP .m a l a r i a e -speci-
fic probes are used as described previously[34,44] with
some modifications in the fluorophore- and quencher-
chemistry. Minor groove binding (MGB) probes are
replaced by XS probes and to accommodate the specific
fluorophor combination of the CFX system the P. falci-
parum-specific XS-probe is labelled with Yakima Yellow,
the P. ovale-specific XS-probe is labelled with Texas Red
and the P. malariae-specific probe is labelled with Qua-
sar-705. An additional P. ovale-type 2 XS-probe (Texas
Red 5’-TCCAAAAGGAATTTTCTTATT-3’-XSQ) is
used for sensitive detection of the P. ovale genetic var-
iant type 2 (GenBank accession X99790/J001527).
Amplification reactions of each DNA sample are per-
formed in white PCR plates, in a volume of 25 μlw i t h
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12.5 pmol of each Plasmodium-specific primer and
15 pmol of each PhHV-1-specific primer, 1.5 pmol of each
P. falciparum, P. vivax-, P. malariae-specific XS-probes,
and PhHV-1-specific Cy5 double-labelled detection probe,
and 2.5 pmol of each P. ovale-specific XS-probes (Biole-
gio), and 5 μl of the DNA sample were used.
Amplification, detection, and analysis are performed as
described for the faecal PCR.
Immunological Measurements
Whole blood culture and cytokine measurements
Blood samples (6 ml) are drawn into Vacutainers (BD,
Franklin Lakes, NJ, USA) containing sodium heparin as
anticoagulant. Within 6 hours, blood cultures are set up
according to methods that were optimized and tested
under field conditions during pilot studies. The hepari-
nized blood is diluted 1:4 with RPMI 1640 medium
(Invitrogen, Breda, The Netherlands) (supplemented
with 2 mM glutamate, 1 mM pyruvate, 100 IU penicillin
and 100 μg/ml streptomycin) and cultured in 96 well
round bottomed plates in 37°C with 5% CO2. Stimula-
tions were performed with medium/control, PHA (2 μg/
m l ,W e l l c o m eD i a g n o s t i c s ,D a r f o r d ,U K ) ,L P S( 1n g / m l
Sigma-Aldrich, Zwijndrecht, The Netherlands), Pam3Cys
(100 ng/ml, Cayla-InvivoGen Europe, Toulouse, France),
PolyIC (50 μg/ml, Cayla-InvivoGen Europe, Toulouse,
France), Ascaris antigen (20 μg/ml, as prepared by van
Riet E et al [45]), iRBC (1 × 10
6,p r e p a r e db yR a d b o u d
University Nijmegen Medical Centre, Nijmegen, The
Netherlands[46]), uRBC (1 × 10
6,p r e p a r e db yR a d b o u d
University Nijmegen Medical Centre, Nijmegen, The
Netherlands [46]). Supernatants are collected on day 1
(unstimulated control, LPS, Pam3Cys) and day 3 (unsti-
m u l a t e dc o n t r o l ,P H A ,A s c a r i s ,i R B C ,u R B C ,P o l y I C ) .
Cytokine concentrations in supernatants are assessed by
means of immunobead-based multiplex assays. This is
an assay that permits simultaneous quantification of
multiple cytokines in a small sample volume. Panels of
capture antibody-coated beads and labeled detection
antibodies are purchased from Bio Source (Camarillo,
California, USA). The cytokines measured will represent
pro- and anti-inflammatory, Th1 and Th2 cytokines:
TNF-a and IL-10 from day 1 supernatants as well as IL-
2, IL-5, IL-10, IFN-g, and TNF-a for day 3 supernatants.
Analysis will be performed on a Liquichip 200® Work-
station (Qiagen, Venlo, The Netherlands) using Liqui-
chip analyzer software (Qiagen, Venlo, The
Netherlands).
Total IgE
Total IgE will be measured as described previously [47].
Briefly, maxisorp plates (Thermo Fisher Scientific, Ros-
kilde, Denmark) are coated overnight with 100 μl/well
rabbit anti-human IgE (Dako, Glostrup, Denmark) at 1/
1400 dilution in 0.1 M carbonate buffer. Plates are
blocked with 100 μl/well phosphate buffered saline
(PBS) containing 5% bovine serum albumin (BSA, Albu-
min Fraction V, Boehringer, Mannheim, Germany). Sera
to be tested are diluted 1:200 in PBS containing 5% fetal
calf serum (FCS, Greiner Bio-One, Alphen a/d Rijn,
Netherlands). A positive standard serum containing
human IgE (NIBSC, Potters Bar, UK) is diluted down 1/3
in a series from 90 IU/ml until a final concentration
0.12 IU/ml on each plate and incubated for 1 hour at
room temperature. After washing step, IgE biotinylated
goat anti-human IgE antibody (1/1000 (Vector Labora-
tories, Burlingame, CA, USA)) is added followed by
Streptavidin Alkaline Phosphatase conjugate (1/3000
(Boehringer, Mannheim, Germany)). The colour is devel-
oped by addition of para-nitrophenylphosphate substrate
(p-NPP (Boehringer, Mannheim, Germany)) diluted
in diethanolamine buffer (DEA, 0.5 mM Mg CL2, 0.1
M DEA, pH 9.6 (Merck, Darmstadt, Germany) and opti-
cal density is measured at 405 nm.
Statistical analyses
A database using MS Access is developed for this study.
At baseline, we will analyze whether helminth infected
subjects are at a higher risk of having P. falciparum or
P. vivax infections in terms of presence of infection and
intensity. The effect of anthelminthic treatment will be
assessed 1 and 2 years after treatment by analyzing the
prevalence ratios as well as the incidence ratios of
malaria infection (clinical cases and parasitemia). In
addition, treatment will be compared with placebo for
reduction of helminth infection and is based on an
intention to treat principle, in anticipation of individual
movement between treatment groups. Cytokine profiles
in response to parasite antigens will be analyzed for
levels of pro- and anti-inflammatory cytokines.
The characterization of immune responses to hel-
minth infections, malaria infections and co-infections
will be assessed prior to treatment using linear regres-
sion [48]. As cytokine levels are non-normally distribu-
ted, we will use log-transformed cytokine data for all
analyses regarding effect of helminth treatment on cyto-
kine profile and susceptibility to plasmodium infection.
For these analyses, multilevel modeling will be used and
the use of longitudinal data will take into account
repeated measurements [48]. Any bias related to selec-
tion of participants and outcome of treatment will be
assessed by comparing individuals that are lost to fol-
low-up and individuals that are not lost and will be
compared on the basis of their baseline characteristics,
age, gender, village, and socioeconomic status and para-
sitic infections. A similar assessment will also be under-
taken to compare the characteristics of individuals in
the treatment and placebo groups at inclusion into the
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proportions.
Multiple regression analysis will be used to determine
1) the association between helminth infections (either all
helminths or individual species) with malaria parasites
(either all or individual species); 2) the effect of decreas-
ing helminth infection on plasmodia parasitaemia and
incidence of malaria cases and 3) the effect of decreas-
ing helminth infection on immunological responses to
malaria antigen. All analyses will be adjusted for con-
founders such as socioeconomic status, body mass
index, age and sex. During the study any other confoun-
ders that are identified will be used in our analyses.
Power calculation
Unpublished microscopy data from the area showed the
combined prevalence of P. falciparum and P. vivax was
12% in the target population and the helminth infection
(A. lumbricoides, Hookworm, T. trichiura) in the popu-
lation was 60%. As study activities such as active follow-
up and prompt treatment will have an effect on the pre-
valence, we expect the malaria prevalence to decrease to
an estimated 6%. Based on these findings a power calcu-
lation (given an alpha of 0.05 and a power of 0.80) gave
a sample size of 749 study subjects needed, in order to
detect a 50% reduction or increase in the prevalence of
plasmodia after 2 years of anthelminthic treatment. The
effect of treatment will presumably be present in hel-
minth carriers only and as an estimated 60% will be car-
riers of helminths during study period, giving an
estimated 1248 subjects in each study arm will be
needed. Allowing for an estimated 20% lost to follow-up
due to movement and refusal, we would need to include
1495 participants in each arm.
Ethical consideration and trial registration, information,
recruitment and consent
This study was approved by The Ethical Committee of
Faculty of Medicine, University of Indonesia, ref: 194/
PT02.FK/Etik/2006 and registered as clinical trial ref:
ISRCTN83830814 and has been filed by ethics commit-
tee of the Leiden University Medical Center. The study
is reported in accordance with the CONSORT guide-
lines for cluster-randomized studies [49].
The regional health authorities in Ende, the regional
capital, were informed of the study and gave their agree-
ment and support. Socialization took place over a two
year period prior to the study involving staff at the pub-
lic health centre (Puskesmas) and 50 community work-
ers, including training for follow-up of study subjects
keeping the community well-informed and well-engaged.
Through many organized sessions, the village heads
were involved in passing on information about the
study, including the benefits and risks involved. The
longitudinal nature was explained and information
sheets and consent forms (in Bahasa Indonesia) were
distributed. Inhabitants of the area were invited to parti-
cipate in the study, consented either by written signa-
ture or thumb print and were informed that they may
withdraw from the study at any time, for any reason
and without consequences. For children below 15 years
old of age also parent consent was obtained. Probable
illness by burden of helminth infection will be taken
into account by three study doctors that will be present
in the area as well as by collaboration with the Puskes-
mas. Severe cases will be treated directly. The medical
doctors will also give support and treatment to the Pus-
kesmas. After completion of the study the whole popu-
lation will be adequately treated for helminth infections
[32,50].
Description of the population recruited
The study has so far provided data that are shown in a
flow chart given in Figure 2. During registration (Janu-
ary 2007 - April 2008) a total of 4650 individuals were
registered in 753 households. At baseline in (April 2008)
3854 of the registered population are residing in the vil-
lage in 734 household. For the immunological studies
250 households were randomly selected within 734
registered households, to allow for 1065 eligible indivi-
duals (Figure 2).
Table 1 shows age-stratified migration patterns. Most
migration is for seeking employment or education
opportunities and most are male. The median age of the
residents is 20 years while this is 19 for those who move
out of the area. The age pyramid is shown in Figure 3
and is typical for low to middle income countries [51].
The traditional source of income in the area is farm-
ing and fishing while some individuals engage in jobs at
government offices with a few in the private sector (Fig-
ure 4). The education level of the majority over 15 years
of age is elementary school (40.6%) followed by senior
high school (27,2%), and junior high school (18.9%)
while 5.4% has college or University degrees. Around
5.5% is illiterate, either not educated at all or dropped
out from elementary school (Figure 5).
Discussion
Since this large community-based trial provides an
important possibility to undertake a series of evaluations
on the effect of helminth infections on malaria as well
as the control of helminth and malaria at the commu-
nity level, our study could help develop evidence-based
policymaking. This study is unique in that it will provide
data on anthelminthic treatment efficacy and effective-
ness in a defined large population in a developing coun-
try. In conclusion the ImmunoSPIN helminth-malaria
study is the first and currently the only longitudinal
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Table 1 Age distribution of the study population who have stayed or moved out of the study area in 16 months of
period*
Age group
(years)
Staying Moved
Male
(n = 1740)
Female (n = 2087) Total (n = 3827) Male (n = 431) Female (n = 365) Total (n = 796)
0-4 175 (10%) 221 (10.6%) 396 (10.3%) 10 (2.3%) 11 (3%) 21 (2.6%)
5-14 491 (28.2%) 467 (22.4%) 958 (25%) 49 (11.4%) 47 (12.9%) 96 (12.1%)
15-24 353 (20.3%) 412 (19.7%) 765 (20%) 248 (57.5%) 224 (61.4%) 472 (59.3%)
25-34 191 (11%) 305 (14.6%) 496 (13%) 71 (16.5%) 53 (14.5%) 124 (15.6%)
35-44 207 (11.9%) 284 (13.6%) 491 (12.8%) 37 (8.6%) 15 (4.1%) 52 (6.5%)
45-54 160 (9.2%) 198 (9.5%) 358 (9.4%) 8 (1.8%) 8 (2.2%) 16 (2%)
55-64 94 (5,4%) 119 (5.7%) 213 (5.6%) 2 (0.5%) 3 (0.9%) 5 (0.6%)
>=6 5 69 (4%) 81 (3.9%) 150 (3.9%) 6 (1.4%) 4 (1%) 10 (1.3%)
* Data from 4623 of 4650, because 27 individuals was not known for their age or birthday.
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Figure 3 Age pyramid of individuals living in Nangapanda, Flores.
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Page 9 of 12study of helminth and malaria co-infections in Indone-
sia. The study has received enthusiastic support from
the authorities in Ende. At the same time, the study
facilitates the transfer of state of the art technologies in
immunology, molecular biology, epidemiology and sta-
tistics to Indonesia.
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